Healthcare provider profile · identity verified

Sage Naran, MD

Allopathic & Osteopathic Physicians|Family Medicine · BRANDON, FL · NPI 1407971807

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Sage Naran, MD received $18.85 in general payments during 2025 across 1 reported records.

Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 1 associated product.

A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.

Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Jardiance by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$18.85

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Boehringer Ingelheim Pharmaceuticals, Inc.	Unresolved — no canonical attribution shown	$18.85	100.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Education	$18.85	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
JARDIANCE Normalized: jardiance	Drug	Boehringer Ingelheim Pharmaceuticals, Inc.	$18.85	1	2025
Source payment records 2025-11-20 · Boehringer Ingelheim Pharmaceuticals, Inc. · $18.85 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
JARDIANCE jardiance	2025	Jardiance	2024	73	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583	Jardiance · 2024 Exact normalized brand match · 1 Part D row	73	19

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	481	139
Amlodipine Besylate	Amlodipine Besylate	343	90
Lisinopril	Lisinopril	314	84
Levothyroxine Sodium	Levothyroxine Sodium	313	86
Simvastatin	Simvastatin	283	77
Metformin Hcl	Metformin Hcl	280	83
Losartan Potassium	Losartan Potassium	227	65
Rosuvastatin Calcium	Rosuvastatin Calcium	222	64
Montelukast Sodium	Montelukast Sodium	200	67
Pantoprazole Sodium	Pantoprazole Sodium	180	43
Omeprazole	Omeprazole	168	51
Gabapentin	Gabapentin	161	38
Metoprolol Succinate	Metoprolol Succinate	155	45
Tamsulosin Hcl	Tamsulosin Hcl	139	39
Ozempic	Semaglutide	124	24
Alprazolam	Alprazolam	121	37
Hydrochlorothiazide	Hydrochlorothiazide	120	38
Meloxicam	Meloxicam	113	43
Albuterol Sulfate Hfa	Albuterol Sulfate	111	31
Potassium Chloride	Potassium Chloride	100	39
Tramadol Hcl	Tramadol Hcl	99	26
Furosemide	Furosemide	98	32
Zolpidem Tartrate	Zolpidem Tartrate	96	20
Escitalopram Oxalate	Escitalopram Oxalate	95	29
Metoprolol Tartrate	Metoprolol Tartrate	92	32
Fluticasone Propionate	Fluticasone Propionate	89	36
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	87	27
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	82	19
Buspirone Hcl	Buspirone Hcl	81	21
Glimepiride	Glimepiride	79	21
Fenofibrate	Fenofibrate	77	18
Jardiance	Empagliflozin	73	19
Tizanidine Hcl	Tizanidine Hcl	73	39
Carvedilol	Carvedilol	71	22
Januvia	Sitagliptin Phosphate	68	21
Hydroxyzine Pamoate	Hydroxyzine Pamoate	67	21
Pravastatin Sodium	Pravastatin Sodium	67	17
Diclofenac Sodium	Diclofenac Sodium	65	21
Ezetimibe	Ezetimibe	65	20
Allopurinol	Allopurinol	64	21
Azithromycin	Azithromycin	64	50
Methylprednisolone	Methylprednisolone	61	51
Trazodone Hcl	Trazodone Hcl	61	13
Eliquis	Apixaban	60	17
Propranolol Hcl	Propranolol Hcl	55	13
Sertraline Hcl	Sertraline Hcl	55	17
Pioglitazone Hcl	Pioglitazone Hcl	54	17
Famotidine	Famotidine	52	19
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	49	14
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	47	suppressed
Ibuprofen	Ibuprofen	47	17
Clopidogrel	Clopidogrel Bisulfate	44	16
Alendronate Sodium	Alendronate Sodium	43	suppressed
Celecoxib	Celecoxib	43	14
Olmesartan Medoxomil	Olmesartan Medoxomil	43	14
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	42	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	41	suppressed
Glipizide	Glipizide	41	11
Valacyclovir	Valacyclovir Hcl	39	13
Atenolol	Atenolol	38	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	35	28
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	35	26
Spironolactone	Spironolactone	35	suppressed
Bupropion Xl	Bupropion Hcl	34	11
Metformin Hcl Er	Metformin Hcl	33	11
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	32	suppressed
Nifedipine Er	Nifedipine	31	suppressed
Ondansetron Hcl	Ondansetron Hcl	31	15
Rybelsus	Semaglutide	30	suppressed
Clonidine Hcl	Clonidine Hcl	29	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	27	24
Esomeprazole Magnesium	Esomeprazole Magnesium	27	suppressed
Naproxen	Naproxen	26	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	26	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	25	suppressed
Farxiga	Dapagliflozin Propanediol	24	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	24	suppressed
Benazepril Hcl	Benazepril Hcl	23	suppressed
Duloxetine Hcl	Duloxetine Hcl	23	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	23	suppressed
Sildenafil Citrate	Sildenafil Citrate	23	suppressed
Mirtazapine	Mirtazapine	22	suppressed
Mometasone Furoate	Mometasone Furoate	22	suppressed
Levetiracetam	Levetiracetam	21	suppressed
Pregabalin	Pregabalin	21	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	21	12
Valsartan	Valsartan	21	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	20	suppressed
Baclofen	Baclofen	20	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	20	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	19	15
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	19	suppressed
Zafirlukast	Zafirlukast	19	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	18	suppressed
Pioglitazone-Metformin	Pioglitazone Hcl/Metformin Hcl	18	suppressed
Topiramate	Topiramate	18	suppressed
Xarelto	Rivaroxaban	18	suppressed
Clonazepam	Clonazepam	17	suppressed
Paroxetine Hcl	Paroxetine Hcl	17	suppressed
Epinephrine	Epinephrine	16	16
Lansoprazole	Lansoprazole	16	suppressed
Linzess	Linaclotide	16	suppressed
Meclizine Hcl	Meclizine Hcl	16	suppressed
Ropinirole Hcl	Ropinirole Hcl	16	suppressed
Ventolin Hfa	Albuterol Sulfate	16	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	15	suppressed
Bupropion Hcl Sr	Bupropion Hcl	14	suppressed
Methocarbamol	Methocarbamol	14	suppressed
Symbicort	Budesonide/Formoterol Fumarate	14	suppressed
Synthroid	Levothyroxine Sodium	14	suppressed
Terbinafine Hcl	Terbinafine Hcl	14	11
Acyclovir	Acyclovir	13	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	13	suppressed
Amoxicillin	Amoxicillin	13	11
Finasteride	Finasteride	13	suppressed
Levemir Flexpen	Insulin Detemir	13	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	13	suppressed
Fluconazole	Fluconazole	12	11
Insulin Syringe	Syringe And Needle,insulin,1ml	12	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	12	suppressed
Prednisone	Prednisone	12	11
Chlorthalidone	Chlorthalidone	11	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	11	suppressed
Mupirocin	Mupirocin	11	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	11	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	11	11

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$18.85 · 1 records	Boehringer Ingelheim Pharmaceuticals, Inc.	JARDIANCE	1	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Jardiance play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error